Mebutamate

CHEMBL1200922 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
232.3 g/mol
LogP
1.4
Phase
4

This sedative and muscle relaxant belonging to the carbamate drug class was used to treat anxiety and tension, working by enhancing inhibitory signals in the central nervous system. It is no longer in common use due to better-tolerated alternatives and concerns about dependence.

Masse moléculaire

232,2800 g/mol

LogP

1,40

TPSA

105,00 Ų

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(C)C(C)(COC(N)=O)COC(N)=O

InChI

InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)

Molecular Formula

C10H20N2O4

HBD / HBA

2 / 4

Liaisons Rotatives

8

Atomes Lourds

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This sedative and muscle relaxant belonging to the carbamate drug class was used to treat anxiety and tension, working by enhancing inhibitory signals in the central nervous system. It is no longer in common use due to better-tolerated alternatives and concerns about dependence.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Mebutamate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200922. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6151. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.